The Brugada Syndrome: Pharmacological Therapy

Overview

Journal Eur Heart J Suppl

Publisher Oxford University Press

Date 2023 May 1

PMID 37125314

Authors

Carla Giustetto

Natascia Cerrato

Veronica Dusi

Filippo Angelini

Gaetano De Ferrari

Fiorenzo Gaita

Affiliations

Soon will be listed here.

Abstract

Brugada syndrome is an inherited channelopathy with an increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias (VA) and an increased incidence of supraventricular arrhythmias, as compared with the general population. For the prevention of SCD, the guidelines recommend the implantable cardioverter-defibrillator (ICD); however, ICD does not prevent VA. In this article, we provide a brief review of the literature on the Brugada syndrome pharmacological therapy, mainly focusing on quinidine treatment. The efficacy of quinidine therapy in the prevention of VA in Brugada syndrome has been demonstrated by several small studies in patients with ICD and recurrent shocks or in asymptomatic patients with inducible ventricular fibrillation (VF) at electrophysiological study. Quinidine has also been tested for the prophylaxis of supraventricular arrhythmias, especially atrial fibrillation/flutter, and in paediatric patients. In these studies, quinidine proved highly effective in preventing re-induction of VF and spontaneous recurrences of both ventricular and supraventricular arrhythmias. Unfortunately, this therapy is burdened by a high incidence of side effects, which may lead to drug discontinuation.

Citing Articles

Artemisinin-Quinidine Combination for Suppressing Ventricular Tachyarrhythmia in an Ex Vivo Model of Brugada Syndrome.

Jeong H, Yoon N, Kim Y, Lee K, Park H J Korean Med Sci. 2025; 40(1):e2.

PMID: 39763307 PMC: 11707659. DOI: 10.3346/jkms.2025.40.e2.

Zebrafish as a Model System for Brugada Syndrome.

Verkerk L, Verkerk A, Wilders R Rev Cardiovasc Med. 2024; 25(9):313.

PMID: 39355588 PMC: 11440409. DOI: 10.31083/j.rcm2509313.

Management of Ventricular Arrhythmias in Heart Failure: Can Less Be More?.

Frankel E, Ho R Curr Cardiol Rep. 2024; 26(10):1097-1103.

PMID: 39080150 DOI: 10.1007/s11886-024-02107-5.

Structural basis of connexin-36 gap junction channel inhibition.

Ding X, Aureli S, Vaithia A, Lavriha P, Schuster D, Khanppnavar B Cell Discov. 2024; 10(1):68.

PMID: 38890333 PMC: 11189382. DOI: 10.1038/s41421-024-00691-y.

Brugada syndrome: identification of subjects at risk and therapy.

Gaita F, Cerrato N, Giustetto C, Garberoglio L, Calo L Eur Heart J Suppl. 2024; 26(Suppl 1):i69-i73.

PMID: 38867864 PMC: 11167981. DOI: 10.1093/eurheartjsupp/suae021.

References

Andorin A, Behr E, Denjoy I, Crotti L, Dagradi F, Jesel L . Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm. 2016; 13(6):1274-82. DOI: 10.1016/j.hrthm.2016.02.013. View

Andorin A, Gourraud J, Mansourati J, Fouchard S, Marec H, Maury P . The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk. Heart Rhythm. 2017; 14(8):1147-1154. DOI: 10.1016/j.hrthm.2017.04.019. View

Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E . Atrial fibrillation in a large population with Brugada electrocardiographic pattern: prevalence, management, and correlation with prognosis. Heart Rhythm. 2014; 11(2):259-65. DOI: 10.1016/j.hrthm.2013.10.043. View

Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D . Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005; 111(5):659-70. DOI: 10.1161/01.CIR.0000152479.54298.51. View

Yan G, Antzelevitch C . Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999; 100(15):1660-6. DOI: 10.1161/01.cir.100.15.1660. View

Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P . Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004; 25(10):879-84. DOI: 10.1016/j.ehj.2004.01.004. View

Sacher F, Probst V, Iesaka Y, Jacon P, Laborderie J, Mizon-Gerard F . Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006; 114(22):2317-24. DOI: 10.1161/CIRCULATIONAHA.106.628537. View

Bouzeman A, Traulle S, Messali A, Extramiana F, Denjoy I, Narayanan K . Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine. Europace. 2013; 16(4):572-7. DOI: 10.1093/europace/eut279. View

Pappone C, Brugada J, Vicedomini G, Ciconte G, Manguso F, Saviano M . Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome. Circ Arrhythm Electrophysiol. 2017; 10(5):e005053. DOI: 10.1161/CIRCEP.117.005053. View

10.

Belhassen B, Glick A, Viskin S . Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004; 110(13):1731-7. DOI: 10.1161/01.CIR.0000143159.30585.90. View

11.

Hermida J, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P . Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004; 43(10):1853-60. DOI: 10.1016/j.jacc.2003.12.046. View

12.

Schimpf R, Giustetto C, Eckardt L, Veltmann C, Wolpert C, Gaita F . Prevalence of supraventricular tachyarrhythmias in a cohort of 115 patients with Brugada syndrome. Ann Noninvasive Electrocardiol. 2008; 13(3):266-9. PMC: 6932135. DOI: 10.1111/j.1542-474X.2008.00230.x. View

13.

Belhassen B, Glick A, Viskin S . Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009; 32(3):294-301. DOI: 10.1111/j.1540-8159.2008.02235.x. View

14.

Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel B, Behr E, Blom N . 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40):3997-4126. DOI: 10.1093/eurheartj/ehac262. View

15.

Serdoz L, Rittger H, Furlanello F, Bastian D . Quinidine-A legacy within the modern era of antiarrhythmic therapy. Pharmacol Res. 2019; 144:257-263. DOI: 10.1016/j.phrs.2019.04.028. View

16.

Kyriazis K, Bahlmann E, van der Schalk H, Kuck K . Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram. Europace. 2009; 11(5):665-6. DOI: 10.1093/europace/eup070. View

17.

. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation. 1991; 84(4):1831-51. DOI: 10.1161/01.cir.84.4.1831. View

18.

Murakami M, Nakamura K, Kusano K, Morita H, Nakagawa K, Tanaka M . Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol. 2010; 56(4):389-95. DOI: 10.1097/FJC.0b013e3181f03c2f. View

19.

Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S . Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996; 27(5):1061-70. DOI: 10.1016/0735-1097(95)00613-3. View

20.

Tsuchiya T, Ashikaga K, Honda T, Arita M . Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2002; 13(7):698-701. DOI: 10.1046/j.1540-8167.2002.00698.x. View